SuperworthParabilis Medicines revenue PBLS
Sales by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $148K
Parabilis Medicines' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $148K.
Revenue over time
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier |
|---|---|---|---|
| Q2 FY26 | $148K | n/a | |
| Q1 FY26 | $0 | n/a | |
| Q2 FY25 | $0 | n/a | |
| Q1 FY25 | $0 | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Parabilis Medicines' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| PBLSParabilis Medicines | n/m | |
| NRIXNurix Therapeutics | $701.9M | |
| OGNOrganon | $6.1B | −2% a year |
| LQDALiquidia | $450.9M | |
| ARQTArcutis Biotherapeutics | $464M | +76% a year |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| INDVIndivior Pharmaceuticals | $1.3B | +13% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| KNSAKiniksa Pharmaceuticals International | $840.8M | +59% a year |
| Peer median | $969.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Parabilis Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.